Iterum Therapeutics Plc(ITRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITRM Iterum Therapeutics Plc

Post-Market Trading 11-22 18:23:55 EST

1.81

+0.04

+2.26%

盘后1.76

-0.05-2.76%

18:23 EST

High1.85	Low1.69	Vol820.35K
Open1.80	D1 Closing1.77	Amplitude9.04%
Mkt Cap49.80M	Tradable Cap48.45M	Total Shares27.52M
T/O1.46M	T/O Rate3.06%	Tradable Shares26.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ITRM","market":"US","secType":"STK","nameCN":"Iterum Therapeutics Plc","latestPrice":1.81,"timestamp":1732309200000,"preClose":1.77,"halted":0,"volume":820345,"hourTrading":{"tag":"盘后","latestPrice":1.76,"preClose":1.81,"latestTime":"18:23 EST","volume":7052,"amount":12650.2245584,"timestamp":1732317833288},"delay":0,"floatShares":26770100,"shares":27515926,"eps":-1.873409,"marketStatus":"Post-Market Trading","change":0.04,"latestTime":"11-22 18:23:55 EST","open":1.8,"high":1.85,"low":1.69,"amount":1462007.702308,"amplitude":0.090395,"askPrice":1.81,"askSize":100,"bidPrice":1.74,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.873409,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732323600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1527220800000,"exchange":"NASDAQ","adjPreClose":1.77,"preHourTrading":{"tag":"盘前","latestPrice":1.8385,"preClose":1.77,"latestTime":"09:29 EST","volume":49550,"amount":91292.83262999999,"timestamp":1732285753384},"postHourTrading":{"tag":"盘后","latestPrice":1.76,"preClose":1.81,"latestTime":"18:23 EST","volume":7052,"amount":12650.2245584,"timestamp":1732317833288},"volumeRatio":0.793804},"requestUrl":"/m/hq/s/ITRM/tweets","defaultTab":"tweets","newsList":[{"id":"2485440728","title":"Iterum Therapeutics Shares Rise After Regaining Compliance With Nasdaq's Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2485440728","media":"MT Newswires Live","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485440728?lang=en_us&edition=fundamental","pubTime":"2024-11-22 04:53","pubTimestamp":1732222399,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics (ITRM) shares were up 9.2% in recent trading on Thursday after the company said it got written notice from the Nasdaq's Listing Qualifications Staff about regaining compliance with continued listing requirements.Price: 1.78, Change: +0.15, Percent Change: +9.20","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4007","BK4585","NQmain","NDAQ","BK4112","BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","ITRM","LENZ","IE00B64PRP62.GBP",".IXIC","LU2210149790.SGD"],"gpt_icon":0},{"id":"2485491859","title":"Iterum Therapeutics regains full Nasdaq compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2485491859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485491859?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:41","pubTimestamp":1732196479,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics (ITRM) announced receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/iterum-therapeutics-regains-full-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/iterum-therapeutics-regains-full-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","PSQ","BK4588","SQQQ","BK4007","IE00B64PRP62.GBP","MNQmain","QID","LU2210150020.SGD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","ITRM","NQmain",".IXIC","BK4139","IE00B3QW5Z07.USD","BK4585","TQQQ","LENZ","QLD"],"gpt_icon":0},{"id":"2485496106","title":"Iterum Therapeutics Regains Full Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2485496106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485496106?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:30","pubTimestamp":1732195800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA994D60:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","NDAQ","BK4585","ITRM","IE00BKPKM429.USD","BK4007","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2483813312","title":"Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483813312","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483813312?lang=en_us&edition=fundamental","pubTime":"2024-11-15 15:10","pubTimestamp":1731654648,"startTime":"0","endTime":"0","summary":"Total Operating Expenses: $4.9 million in Q3 2024, down from $16.7 million in Q3 2023.Research and Development Costs: $3.1 million in Q3 2024, compared to $14.9 million in Q3 2023.General and Administrative Costs: $1.8 million in Q3 2024, consistent with Q3 2023.Net Loss : $6.1 million in Q3 2024, compared to $3.9 million in Q3 2023.Net Loss : $4.8 million in Q3 2024, compared to $15.7 million in Q3 2023.Cash, Cash Equivalents, and Short-term Investments: $14.5 million at the end of September 2024.Ordinary Shares Outstanding: Approximately 27.5 million as of November 4, 2024.Exchangeable Notes Outstanding: Approximately $11.1 million, exchangeable for about 1.9 million shares.Regulatory Milestone Payment to Pfizer: $20 million deferred for two years via promissory note.Iterum Therapeutics PLC  received FDA approval for Arlinda, an oral sulopenem product, marking the first U.S. approval of an oral product in the penem class of drugs.Iterum Therapeutics PLC  expects to fund operations in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xLPb9Flv0ynuPxcOLBxObQ--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/3a8f94d861a8c832d0cb4402a841c877","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xLPb9Flv0ynuPxcOLBxObQ--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/3a8f94d861a8c832d0cb4402a841c877"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iterum-therapeutics-plc-itrm-q3-071048687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ITRM","PFE"],"gpt_icon":0},{"id":"2483332120","title":"Iterum Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483332120","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483332120?lang=en_us&edition=fundamental","pubTime":"2024-11-15 04:59","pubTimestamp":1731617941,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics PLC reports results for the quarter ended September 30 - Earnings SummaryIterum Therapeutics PLC ITRM.OQ reported a quarterly adjusted loss of 30 cents per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL8N3ML2TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM"],"gpt_icon":0},{"id":"2483876206","title":"Iterum Therapeutics Q3 2024 Adj. EPS $(0.24) Misses $(0.20) Estimate. Cash And Equivalents Of $14.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876206","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876206?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:03","pubTimestamp":1731585781,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.20) by 20 percent. This is a 80 percent increase over losses of $(1.20) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41967762/iterum-therapeutics-q3-2024-adj-eps-0-24-misses-0-20-estimate-cash-and-equivalents-of-14-5m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ITRM"],"gpt_icon":0},{"id":"2483876568","title":"Iterum Therapeutics Q3 Adjusted Net Income USD -4.837 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876568?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nPLXFCF639:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2483763708","title":"Iterum Therapeutics Q3 Operating Income USD -4.887 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483763708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483763708?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nPLXFCF639:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2483587638","title":"Iterum Therapeutics Q3 Operating Expenses USD -4.887 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483587638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483587638?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nPLXFCF639:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ITRM","BK4007"],"gpt_icon":0},{"id":"2483876533","title":"Iterum Therapeutics Q3 Net Income USD -6.094 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876533?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nPLXFCF639:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ITRM"],"gpt_icon":0},{"id":"2482700641","title":"Iterum Therapeutics PLC  expected to post a loss of 20 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482700641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482700641?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:58","pubTimestamp":1731419898,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics PLC  expected to post a loss of20cents a share - Earnings Preview Iterum Therapeutics PLC ITRM.OQ ITRM.O is expected to show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ1MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITRM"],"gpt_icon":0},{"id":"2482898927","title":"Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482898927","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482898927?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"DUBLIN and CHICAGO, Nov. 11, 2024  -- Iterum Therapeutics plc  , a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced thatthe Company will release its third quarter 2024 financial results before the open of theU.S.financial markets onThursday, November 14, 2024. Management will host a conference call at8:30 a.m. ETthat day to discuss the Company’s financial results and provide an update on its business.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5n5DQiV9eTLHoDx6WLh1Hw--~B/aD00Mzt3PTIwNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/541083ed986d53eadfcc58efb6727c34","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5n5DQiV9eTLHoDx6WLh1Hw--~B/aD00Mzt3PTIwNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/541083ed986d53eadfcc58efb6727c34"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iterum-therapeutics-report-third-quarter-130000552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","LENZ","ITRM"],"gpt_icon":0},{"id":"2480869537","title":"BRIEF-Iterum Therapeutics defers milestone payment to Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2480869537","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480869537?lang=en_us&edition=fundamental","pubTime":"2024-11-02 06:17","pubTimestamp":1730499468,"startTime":"0","endTime":"0","summary":"Nov 1 (Reuters) - Iterum Therapeutics PLC   :   * ITERUM THERAPEUTICS- NOTIFIED PFIZER, ELECTING TO DEFER MILESTONE PAYMENT FOR 2 YEARS FOR ORLYNVAH, OR UNTIL OCT 25, 2026, DELIVERED NOTE TO PFIZERSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","SG9999003800.SGD","IE00B19Z3581.USD","LU0456855351.SGD","LU1023059063.AUD","LENZ","IE00BLSP4452.SGD","LU1066051498.USD","LU0306806265.USD","SG9999001176.USD","BK4139","LU0225771236.USD","BK4550","LU0306807586.USD","LU0234572021.USD","SGXZ57979304.SGD","LU1894683348.USD","ITRM","LU1883839398.USD","LU0058720904.USD","BK4534","LU0122379950.USD","LU1894683264.USD","BK4007","BK4533","LU1057294990.SGD","LU0289739699.SGD","BK4585","SG9999002224.SGD","SG9999002232.USD","LU0321505439.SGD","IE00B19Z3B42.SGD","BK4588","IE0002270589.USD","SG9999011175.SGD","LU0170899867.USD","SG9999013999.USD","BK4592","IE000M9KFDE8.USD","LU0985481810.HKD","LU1066053197.SGD","BK4581","LU0321505868.SGD","LU0868494617.USD","LU0225284248.USD","BK4568","SG9999001176.SGD","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2480633978","title":"Iterum Therapeutics- Notified Pfizer, Electing to Defer Milestone Payment for 2 Years for Orlynvah, or Until Oct 25, 2026, Delivered Note to Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2480633978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480633978?lang=en_us&edition=fundamental","pubTime":"2024-11-02 05:19","pubTimestamp":1730495994,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nFWN3M81ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ITRM"],"gpt_icon":0},{"id":"2479283966","title":"Iterum Therapeutics (ITRM) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2479283966","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479283966?lang=en_us&edition=fundamental","pubTime":"2024-10-29 21:45","pubTimestamp":1730209516,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy maintained a Buy rating on Iterum Therapeutics (ITRM – Research Report) yesterday. The company’s shares opened t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/iterum-therapeutics-itrm-receives-a-buy-from-maxim-group?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/iterum-therapeutics-itrm-receives-a-buy-from-maxim-group?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ITRM"],"gpt_icon":0},{"id":"2479590224","title":"Nasdaq Wrap: Nvidia overtakes Apple as world’s most valuable, as investors brace for election volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2479590224","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479590224?lang=en_us&edition=fundamental","pubTime":"2024-10-29 04:30","pubTimestamp":1730147449,"startTime":"0","endTime":"0","summary":"Nasdaq Wrap is our weekly look at the highly influential, tech-heavy Nasdaq 100 index – movers and shakers over the past seven days or so, talking points and a brief look at what’s ahead.Wall Street faced pullback last week after strong rally. Investors brace for election volatility ahead of key earnings","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/10/Nvidia-surpasses-apple-as-most-valuable-company.-Picture-via-Getty-Images-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/10/Nvidia-surpasses-apple-as-most-valuable-company.-Picture-via-Getty-Images-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stockhead.com.au/nasdaq-wrap/nasdaq-wrap-nvidia-overtakes-apple-as-worlds-most-valuable-as-investors-brace-for-election-volatility/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4588","IE00B7KXQ091.USD","LU0053666078.USD","LU0456855351.SGD","IE000KEQY171.SGD","BK4507","2NVD.UK","AAPL","SQQQ","PSQ","LU2213496289.HKD","QID","BK4548","NQmain","TSLA","NDAQ","IE0005OL40V9.USD","IE000ITXATA3.USD","LU0061474705.USD","LU0130102774.USD","LU0048584097.USD","META","GOOG","GOOGL","IE00BK4W5M84.HKD","LU0289960550.SGD",".IXIC","LU0130517989.USD","L","BK4512","GDP","IE00BJJMRX11.SGD","IE00B4JS1V06.HKD","BK4551","IE00BGHQF748.EUR","3NVD.UK","NVDA","ITRM","AMZN","LU2326559502.SGD","MNQmain","NFLX","TQQQ","BK4576","MSFT","IE0004086264.USD","IE00BYQQ9H92.USD","LU0061475181.USD","IE00BJTD4N35.SGD","QLD","LU1548497426.USD","TSM","HK0000320223.HKD","BK4511"],"gpt_icon":1},{"id":"2478448445","title":"FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2478448445","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478448445?lang=en_us&edition=fundamental","pubTime":"2024-10-28 22:19","pubTimestamp":1730125172,"startTime":"0","endTime":"0","summary":"This is the first approved indication for Orlynvah and the first FDA-approved product for Iterum.The FDA approval was based on a clinical development program, including two Phase 3 clinical trials  that evaluated the safety and efficacy of Orlynvah compared to ciprofloxacin  and Augmentin  in the treatment of adult women with uUTI.“The introduction of novel products, like Orlynvah, is an important way to combat antimicrobial resistance to other approved oral agents and offers a potential solution to patients and physicians,” said Corey Fishman, Iterum’s CEO.“As the first oral penem approved in the U.S., Orlynvahoffers an excellent alternative treatment option for appropriate patients in the underserved uUTI market. With FDA approval and a clear label, we will renew our efforts to achieve a strategic transaction involving Orlynvah with the goal of maximizing value for our stakeholders.”The FDA determined that additional data are necessary to support approval.The agency asked for at leas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6osdtl7yyLeT72R3BabMng--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/14cb9334018802ea1d15c999a72ede5d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6osdtl7yyLeT72R3BabMng--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/14cb9334018802ea1d15c999a72ede5d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approval-orlynvah-urinary-tract-141932122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","CRL","LU0390134368.USD","ITRM","BK4007","BK4588","BK4585","BK4530"],"gpt_icon":1},{"id":"2478489474","title":"Iterum Therapeutics Plc : Maxim Group Raises Target Price to $10 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2478489474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478489474?lang=en_us&edition=fundamental","pubTime":"2024-10-28 21:54","pubTimestamp":1730123666,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nFWN3M41ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ITRM"],"gpt_icon":0},{"id":"2478767561","title":"Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2478767561","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478767561?lang=en_us&edition=fundamental","pubTime":"2024-10-28 17:00","pubTimestamp":1730106000,"startTime":"0","endTime":"0","summary":"Monday, October 28, 20248:30 a.m. Eastern Daylight Time. Dial-in information:United States: +1 833-470-1428 | International: +1 404-975-4839Access code: 936149. The conference call replay will be available in theEvents & Presentations page of Iterum's website following the call.AboutIterum Therapeutics plcIterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH  for the treatment of uncomplicated urinary tract infection","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MK8nP.IQshG5uGKUq8rA5g--~B/aD0xNzM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/48c9fdd0e3a1ef84e139f3dbdb054491","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MK8nP.IQshG5uGKUq8rA5g--~B/aD0xNzM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/48c9fdd0e3a1ef84e139f3dbdb054491"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/iterum-therapeutics-host-morning-conference-090000005.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iterum-therapeutics-host-morning-conference-090000005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4218","HST","CEO","BK4139","ITRM","BK4007","BK4588","BK4585","LENZ"],"gpt_icon":0},{"id":"2478639509","title":"Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs","url":"https://stock-news.laohu8.com/highlight/detail?id=2478639509","media":"seekingalpha","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478639509?lang=en_us&edition=fundamental","pubTime":"2024-10-26 03:07","pubTimestamp":1729883221,"startTime":"0","endTime":"0","summary":"Bet_Noire Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs. The drug, which is Iterum’s first FDA-approved product, is indicated for treatment of uUTIs","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215516118/image_1215516118.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215516118/image_1215516118.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4206808-iterum-stock-rallies-on-fda-approval-of-olynvah-for-utis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4007","SQQQ",".IXIC","NQmain","MNQmain","QID","PSQ","ITRM","QLD","TQQQ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.iterumtx.com","stockEarnings":[{"period":"1week","weight":0.3015},{"period":"1month","weight":0.6389},{"period":"3month","weight":0.4628},{"period":"6month","weight":0.3111},{"period":"1year","weight":-0.1449},{"period":"ytd","weight":-0.1015}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.079617},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01483},{"month":3,"riseRate":0.5,"avgChangeRate":0.065808},{"month":4,"riseRate":0.5,"avgChangeRate":0.010815},{"month":5,"riseRate":0.333333,"avgChangeRate":0.004014},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.075471},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.118993},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.104988},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.113033},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.165968},{"month":11,"riseRate":0.571429,"avgChangeRate":0.342157},{"month":12,"riseRate":0.5,"avgChangeRate":0.087662}],"exchange":"NASDAQ","name":"Iterum Therapeutics Plc","nameEN":"Iterum Therapeutics Plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Iterum Therapeutics Plc(ITRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Iterum Therapeutics Plc(ITRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Iterum Therapeutics Plc,ITRM,Iterum Therapeutics Plc股票,Iterum Therapeutics Plc股票老虎,Iterum Therapeutics Plc股票老虎国际,Iterum Therapeutics Plc行情,Iterum Therapeutics Plc股票行情,Iterum Therapeutics Plc股价,Iterum Therapeutics Plc股市,Iterum Therapeutics Plc股票价格,Iterum Therapeutics Plc股票交易,Iterum Therapeutics Plc股票购买,Iterum Therapeutics Plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Iterum Therapeutics Plc(ITRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Iterum Therapeutics Plc(ITRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction